Verrica Pharmaceuticals grants stock option to new COO as inducement for employment

From GlobeNewswire: 2024-12-09 16:15:00

Verrica Pharmaceuticals Inc. announced the granting of a nonqualified stock option to new COO David Zawitz to purchase 950,000 shares of common stock. The option was awarded as an inducement to Mr. Zawitz’s employment and will vest over time based on his continuous service with the company. Verrica specializes in dermatology therapeutics, with a focus on skin diseases requiring medical interventions. Their product YCANTH® (VP-102) is FDA-approved to treat molluscum contagiosum and is also in development for common warts and genital warts. The company is also developing VP-103 for plantar warts and has a license agreement for VP-315 to treat non-melanoma skin cancers.



Read more at GlobeNewswire: Verrica Reports Inducement Grant Under Nasdaq Listing Rule